This trial has completed recruitment on this platform, and is no longer accepting new referrals.
A research study conducted by Moderna is testing an investigational vaccine that may protect children from two very common viruses called Human Metapneumonovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3), which are known to cause respiratory disease.
Trial ID: NCT04144348
This study is evaluating an investigational combination vaccine, called mRNA-1653, to protect against hMPV and PIV3. Both hMPV and PIV3 are known to cause respiratory disease in people of all ages, often in children.
This study will evaluate the safety and immune responses of the mRNA-1653 vaccine when administered to children ages 1 year and less than 5 years of age who have previously had an infection with both hMPV and PIV3 (this could have been just what seemed like a mild common cold).
There are no approved vaccines to prevent hMPV or PIV3 infections. A safe and effective vaccine against hMPV and PIV3 has the potential to substantially improve the health of young children.
Participation in the mRNA-1653-P102 Study lasts approximately 14 months and includes phone calls and up to eight visits to the study site.
Insurance is not needed to join this clinical trial, and compensation for your time will be available.
You will need to bring your child to one of the study clinics taking part in this clinical trial. Sites are located in:
Not yet Recruiting